336 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 29368 | pancreas | Novartis | DaNIS-2 | Trial closed for recruitment | A randomized, double-blind, phase III study, comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) | 3 | 3 | ||||
| 22829 | No prior exposure to immune-mediated therapy | Thierry Gil | Bladder | AstraZeneca | DANUBE | Trial closed | A Phase III, Randomized, Open-label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Bladder Cancer | thierry.gil@hubruxelles.be | 3 | 3 | |
| 22717 | Progression or intolerance to imatinib | Thierry Gil | Stromal digestive tumors | Deciphera Pharmaceuticals LLC | DCC-2618-03-002 | Trial closed | A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib | thierry.gil@hubruxelles.be | 3 | 3 | |
| 29238 | Andrea Gombos | Breast | Institut Jules Bordet | DECRESCENDO | Trial closed for recruitment | De-Escalation of adjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER2 blOckade | accueil.oncologie@hubruxelles.be | 2 | 2 | ||
| 22691 | any line | Philippe Lewalle | Multiple | Celyad | DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy with NKR-2 | Trial closed | An open-label, Phase I study to assess the safety of NKR-2 treatment administration after a non-myeloablative preconditioning chemotherapy in relapse/refractory acute myeloid leukemia or myelodysplastic syndrome patients | philippe.lewalle@hubruxelles.be | 1 | 1 | |
| 22767 | Conservative or non-conservative breast surgery associated with axillary dissection | Breast | Institut Jules Bordet | DESIGN | Trial closed | The DESIGN trial A randomised, Double-blind, placEbo-controlled Study to assess the effectIveness of pectoral nerves block (Pecs) after breast surGery on Piritramide coNsumption | 3 | 3 | |||
| 28586 | Andrea Gombos | Breast | AstraZeneca | Destiny - Breast06 | Trial closed for recruitment | Phase III Study of Trastuzumab Deruxtecan versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive, Breast Cancer Patients whose Disease has Progressed On Endocrine Therapy in the Metastatic Setting | accueil.oncologie@hubruxelles.be | 3 | 3 | ||
| 29046 | Andrea Gombos | Breast | AstraZeneca | DESTINY- Breast12 | Trial open for recruitment | An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2 Positive Breast Cancer (DESTINY- Breast12) | accueil.oncologie@hubruxelles.be | 3/4 | 3 | ||
| 28869 | Philippe Aftimos | Multiple | AstraZeneca | DESTINY-PAN01 | Trial closed for recruitment | A Phase II, multicenter, open-label study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of unresectable and/or metastatic solid tumors harboring HER2 activating mutations regardless of tumor histology | philippe.aftimos@hubruxelles.be | 2 | 2 | ||
| 22712 | HER2+. Metastatic/unresecable | Andrea Gombos | Breast | Daiichi Sankyo | DS8201-A-U302 | Trial closed for recruitment | DS8201-A-U302 A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer | accueil.oncologie@hubruxelles.be | 3 | 3 | |
| 22713 | HER2 low (+ or ++)/ER+ or ER-. Metastatic | Andrea Gombos | Breast | Daiichi Sankyo | DS8201-A-U303 | Trial closed for recruitment | A phase 3, multicenter, randomized, open-label, active-controlled trial of DS-8201a, an anti-HER2-antibody drug conjugate (ADC), versus treatment of Physician's choice for HER2-low, HR-positive, unresectable and/or metastatic breast cancer subjects (DS8201-A-U303) | accueil.oncologie@hubruxelles.be | 3 | 3 | |
| 29412 | Nuria Kotecki | Multiple | Domain therapeutics | DT-9081-CLI-001 | Trial open for recruitment | A phase 1a, multicenter, open-label, dose-escalation study to determine a recommended clinical dose (RCD) of DT-9081, followed by an expansion study of DT-9081 at RCD in participants with advanced/metastatic solid tumours (DT-9081-CLI-001) | Nuria.Kotecki@hubruxelles.be | 1 | 1 | ||
| 29685 | Mariana Brandao | Lung | Sanofi-Aventis | EFC15858/CARMEN-LC03 | Trial closed for recruitment | Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic Non-Squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors | mariana.brandao@hubruxelles.be | 3 | 3 | ||
| 22818 | HER2+. Age Superior to 70 years old | Lissandra Dal Lago | Breast | EORTC | ELDERLY | Trial closed | Pertuzumab + trastuzumab (PH) versus PH plus metronomic chemotherapy (PHM) in the elderly HER2+ metastatic breast cancer population who may continue on T-DM1 alone following disease progression while on PH / PHM: an open-label multicenter randomized phase II selection trial of the EORTC Elderly Task Force and Breast Cancer Group | lissandra.dallago@hubruxelles.be | 2 | 2 |